These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30123104)

  • 1. The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.
    Cellai L; Carvalho K; Faivre E; Deleau A; Vieau D; Buée L; Blum D; Mériaux C; Gomez-Murcia V
    Front Neurosci; 2018; 12():520. PubMed ID: 30123104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adenosine A
    Launay A; Nebie O; Vijaya Shankara J; Lebouvier T; Buée L; Faivre E; Blum D
    Neuropharmacology; 2023 Mar; 226():109379. PubMed ID: 36572177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of adenosine in Alzheimer's disease.
    Rahman A
    Curr Neuropharmacol; 2009 Sep; 7(3):207-16. PubMed ID: 20190962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
    Flaten V; Laurent C; Coelho JE; Sandau U; Batalha VL; Burnouf S; Hamdane M; Humez S; Boison D; Lopes LV; Buée L; Blum D
    Biochem Soc Trans; 2014 Apr; 42(2):587-92. PubMed ID: 24646282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
    Laurent C; Buée L; Blum D
    Biomed J; 2018 Feb; 41(1):21-33. PubMed ID: 29673549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
    Takahashi RH; Nagao T; Gouras GK
    Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice.
    Ricke KM; Cruz SA; Qin Z; Farrokhi K; Sharmin F; Zhang L; Zasloff MA; Stewart AFR; Chen HH
    J Neurosci; 2020 Feb; 40(7):1581-1593. PubMed ID: 31915254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
    Conway KA; Baxter EW; Felsenstein KM; Reitz AB
    Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
    Isopi E; Granzotto A; Corona C; Bomba M; Ciavardelli D; Curcio M; Canzoniero LM; Navarra R; Lattanzio R; Piantelli M; Sensi SL
    Neurobiol Dis; 2015 Sep; 81():214-24. PubMed ID: 25434488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
    Thal DR; Walter J; Saido TC; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):167-82. PubMed ID: 25534025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease.
    Martinez B; Peplow PV
    Neural Regen Res; 2019 Jul; 14(7):1158-1176. PubMed ID: 30804241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.
    Laurent C; Eddarkaoui S; Derisbourg M; Leboucher A; Demeyer D; Carrier S; Schneider M; Hamdane M; Müller CE; Buée L; Blum D
    Neurobiol Aging; 2014 Sep; 35(9):2079-90. PubMed ID: 24780254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular biomarkers of Alzheimer's disease.
    Heaton GR; Davis BM; Turner LA; Cordeiro MF
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):117-25. PubMed ID: 25788142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.